Charles Schwab Investment Management Inc Uro Gen Pharma Ltd. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 90,493 shares of URGN stock, worth $999,042. This represents 0.0% of its overall portfolio holdings.
Number of Shares
90,493
Previous 82,917
9.14%
Holding current value
$999,042
Previous $1.39 Million
17.4%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$41.8 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$41.2 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$25.4 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$24.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$24.1 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $251M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...